All In Biotech

Drug Trial Radar · NCT01597440

Long-term Outcome of N-Carbamylglutamate Treatment in Propionic Acidemia and Methylmalonic Acidemia

Last checked: Nov 20, 2026Latest source record: Apr 26, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

1

Actual

Start

Sep 2012

Primary completion

Feb 2015

Study completion Feb 2015

Sponsor

Lead sponsor
Mendel TuchmanAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Children's National Research Institute; Boston Children's Hospital; University Hospitals Cleveland Medical Center; University of California, Los Angeles; Children's Hospital of Philadelphia; Lucile Packard Children's Hospital; University of Colorado, Denver
First posted
May 14, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 1 hour, up to 4 weeks
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Background: Very few drugs exist that treat hyperammonemia, specifically PA and MMA. Diet restrictions and alternate pathway agents are the current primary treatments, but they frequently fail to prohibit brain damage. Orthotopic liver transplantation cures the hyperammonemia of urea cycle disorders, but organ availability is limited and the procedure is highly invasive and requires life-long immunosuppression. A drug that could repair or stimulate a dysfunctional urea cycle such as this would have several advantages over current therapy. A drug called N-carbamyl-L-glutamate, Carglumic acid (NCG or Carbaglu)has recently been found to be virtually curative of another urea cycle defect called NAGS deficiency. In this disorder, treatment with NCG alone normalizes ureagenesis, blood ammonia and glutamine levels, allows normal protein tolerance and restores health. Knowledge from this study is being applied to acquired hyperammonemia, specifically in patients with propionic PA and MMA, to try and improve neurodevelopmental outcomes by improving the hyperammonemia. Aims: The overall objective of this project is to determine whether treatment of acute hyperammonemia with Carglumic acid in propionic acidemia (PA), methylmalonic acidemia (MMA) changes the long-term outcome of disease and to determine if it is effective in restoring urine ammonia levels to normal levels.

Conditions

  • Propionic Acidemia
  • Methylmalonic Acidemia

Interventions

  • N-carbamylglutamateDrug

    Active NCG \& Standard of Care Chemical Composition: N-carbamyl-L-glutamic acid (NCG) The daily dose will be 100 mg/kg/ day. The doses are to be divided into 2 equal doses and administered orally or enterally by nasogastric or gastrostomy tube (standard of care will prevail when choosing the mode of drug administration). The tablets must be dispersed in a minimum of 2.5-10 ml of water and ingested immediately or administered by fast push through a syringe via a nasogastric or gastrostomy tube. The suspension has a slightly acidic taste. This drug will be administered for 7 days after admission or until discharge (whichever is sooner).

  • Standard of CareOther

    Standard of Care

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. NeurodevelopmentTime frame: 30 months

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • University of California Los Angeles

    Los Angeles, California

  • Lucile Packard Children's Hospital at Stanford

    Palo Alto, California

  • The Children's Hospital of Colorado

    Aurora, Colorado

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • Children's Hospital Boston

    Boston, Massachusetts

  • University Hospitals of Cleveland/Rainbow Babies and Children's Hospital

    Cleveland, Ohio

  • The Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.